Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (NASDAQ:CRSP ) Innovation Day Conference Call June 21, 2022 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Phuong Khanh Morrow - Chief Medical Officer Sumanta Kumar Pal - Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope Susan Kim - Vice President of Corporate Communications & Investor Relations Jon Terrett - Head of Research Swaminathan Iyer - Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas Alireza Rezania - Senior Vice President, Head of Regenerative Medicine Conference Call Participants Raju Prasad - William Blair Joon Lee - Truist Securities Liisa Bayko - Evercore Tyler Van Buren - Cowen Ted Tenthoff - Piper Sandler Yigal Nochomovitz - Citi Tony Butler - ROTH Capital Gil Blum - Needham & Company Silvan Tuerkcan - JMP Securities Cheng Li - Oppenheimer Elizabeth Webster - Goldman Sachs Samarth Kulkarni [Call starts abruptly] Innovation Day. It's great to see you, many familiar faces and some new ones.

CRISPR Therapeutics AG (CRSP) Management Presents at Innovation Day Conference (Transcript)

CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene-editing company focused on developing gene-based medicines for human diseases, has risen a solid 24% in a month, outperforming the broader markets with the S&P500 down 8%.

Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels?

CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?

CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets. The CRISPR Therapeutics Analyst: Kostas Biliouris initiated coverage of CRISPR Therapeutics with an Outperform.

3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner

CRISPR Therapeutics AG (NASDAQ:CRSP ) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 12:20 PM ET Company Participants Salveen Richter - Goldman Sachs Conference Call Participants Lawrence Klein - Chief Operating Officer Salveen Richter Good morning, everyone. Thanks for joining us.

CRISPR Therapeutics AG (CRSP) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)

Axsome Therapeutics

The market hasn't been kind to these two stocks lately.

2 Top Biotech Stocks Ready for Bull Runs

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies. CTX130 was well tolerated across all dose levels.

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive

ARK Innovation ETF

Roku

Block

Tesla

The ARK Innovation ETF has fallen about 65% in the past year as investors fled from growth stocks.

Roku, Tesla, and Other Cathie Wood Favorites Are Falling

-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90% of patients-

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Vertex Pharmaceuticals

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announce presentation of new data on exa-cel, formerly known as CTX001™, from CLIMB-111, CLIMB-121 and CLIMB-131 highlighting the potentially transformative profile of this investigational therapy for people with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) and provided additional program updates. New Data fo

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

Beam Therapeutics

Exact Sciences

Intellia Therapeutics

Teladoc

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

5 Health Care Stocks Cathie Wood Favors

Biogen

CinCor Pharma

Emergent BioSolutions

Global Blood Therapeutics

Harmony Biosciences Holdings

Vigil Neuroscience

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.

7 No-Brainer Biotech Stocks to Add to Your Buy List

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report?

ZUG, Switzerland and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 9:20 a.m. Pacific Time (PT).

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Comcast

Crocs

Gilead Sciences

Goldman Sachs

Skyworks Solutions

Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. The post 7 Oversold Stocks to Buy Right Now appeared first on InvestorPlace.

7 Oversold Stocks to Buy Right Now

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress. Vertex also announced three abstracts accepted for poster presentation at EHA. Late-breaking abstract #LB2367 entitled “Efficacy and Safety of A Single Dose of CTX001 For Transfusion-Dependent Βeta-Thalassem

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress

ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will host an Innovation Day focused on early research and development on Tuesday, June 21, 2022 at 2:00 PM ET.

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

Enservco

Longeveron

Martin Midstream Partners

Summit Midstream Partners LP

Volt Information Sciences, Inc.

The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.

How to Buy Stocks in a Recession

ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief Medical Officer, effective May 23, 2022. Dr. Morrow brings more than a decade of leadership experience in global drug development and joins CRISPR Therapeutics to lead the Company's global clinical development and regulatory operations.

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

ARK Industrial Innovation ETF

ARK Space Exploration & Innovation ETF

Shopify

ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider.

5 Cathie Wood Stocks to Buy Now

Moderna

These two companies have been southbound lately.

2 Stocks With 75% to 183% Upside, According to Wall Street

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022, at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online. This will be the first clinical data presented from the CTX130 program.

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks.  The analysts .

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.

CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates

News for CRISPR Therapeutics Stock (CRSP)